News
The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.
FEATURED STORIES
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Bristol Myers Squibb Company forged an oncology drug discovery and development deal valued at more than $1 billion with Volastra Therapeutics.
Zai Lab, a China-focused biopharma company that focuses on treatments for cancer and autoimmune diseases, announced positive data for its clinical trial on Zejula (niraparib) for ovarian cancer.
Albert Bourla, Pfizer’s CEO, took home a salary of $1.69 million in 2021. To Pfizer, he’s undoubtedly worth it, having led the company to its COVID-19 vaccine success.
BMS filed a patent infringement lawsuit against AstraZeneca over Imfinzi, while Guardant Health issued a statement in response to Illumina’s intellectual property lawsuit.
Ztalmy is Marinus’ oral suspension medication for patients ages two years and older who experience seizures linked with cyclin-dependent kinase-like 5 deficiency disorder.
Omega Therapeutics is harnessing the power of epigenetics in an unprecedented way and engineering programmable epigenetic mRNA therapeutics to transform medicine in the service of patients.
Recently, antimicrobial resistance has re-emerged in the public limelight as an increasingly severe global health problem.
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
BMS achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of melanoma.
The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.